Early treatment with deferasirox (Exjade®) in low risk MDS

Trial Profile

Early treatment with deferasirox (Exjade®) in low risk MDS

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2013

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms Exjade-Early-Trial
  • Most Recent Events

    • 11 Aug 2012 Actual end date (17 Jul 2012) added as reported by European Clinical Trials Database record.
    • 17 Jul 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 12 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top